Patients & Survivors

Pediatric brain tumors are the most common type of solid childhood cancer and only second to leukemia as a cause of pediatric malignancies. The prognosis of pediatric brain tumors depends on the age at presentation, …

We are thrilled to announce the release of episode 13 of the Rare Enough Podcast, where we have the privilege of hosting Colin Gerner, the CEO and co-founder of StacheStrong. This episode is set to …

Meet actual users and caregivers at an Optune GioTM Open House! You’ll learn more about Optune Gio, an FDA-approved treatment for GBM. Optune Gio users and care partners will discuss their experiences living with GBM …

Northwest Biotherapeutics is making significant strides in the fight against Glioblastoma multiforme (GBM), the most lethal form of primary brain cancer, with their lead product, DCVax®-L. GBM is a devastating disease with a grim prognosis: …

Join us for our new support group, “Legacy of Hope,” dedicated to caregivers who have lost their loved ones to a brain tumor. We’ve created this group to provide a compassionate and understanding space for …

Glioblastoma (GBM) is one of the most complex, deadly, and treatment-resistant cancers. More than 14,490 Americans are expected to receive a GBM diagnosis in 2023.  It can affect anyone—men, women, and children—regardless of age, background, or lifestyle. GBM does not discriminate based on gender, socioeconomic status, region, age, or political affiliation. Every year, on the third Wednesday of July, GBM Awareness Day is observed to acknowledge the profound impact of this devastating disease and to emphasize the national imperative to advance research, raise awareness, and take action toward finding a cure for glioblastoma.Glioblastoma Awareness Day is a vital opportunity to …

We are thrilled to announce the release of episode 13 of the Rare Enough Podcast, where we have the privilege of hosting Colin Gerner, the CEO and co-founder of StacheStrong. This episode is set to …

Imvax, a national sponsor for Head for the Cure, has made significant strides in cancer research, recently announcing the completion of enrollment in their Phase 2b clinical trial of IGV-001. This milestone, coupled with successful …

Courtney Watson and I embarked on an unforgettable journey to Chicago for our first ASCO (American Society of Clinical Oncology) conference, representing Head for the Cure. Our excitement and anticipation were palpable as we navigated …

We are thrilled to announce the release of episode 13 of the Rare Enough Podcast, where we have the privilege of hosting Colin Gerner, the CEO and co-founder of StacheStrong. This episode is set to …